Mezzion Pharma Co.Ltd(140410)

Description: Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

---

Keywords: Organic Compounds Chemical Compounds Hypertension Chronic Obstructive Pulmonary Disease Respiratory Diseases Vascular Disease Erectile Dysfunction Pulmonary Arterial Hypertension Benign Prostatic Hyperplasia Pulmonary Hypertension Lactams Overactive Bladder Treatment Of Vascular Diseases Cgmp Specific Phosphodiesterase Type 5 Heterocyclic Compounds Pde5 Inhibitors

---

Home Page: www.mezzion.co.kr

C&H Building
Seoul,
South Korea
Phone: 82 2 560 8000

---

Officers

Exchange: KQ

Country: KR : Korea (Republic of)

Currency: Korean Won (₩)